Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03671083 · ClinicalTrials.gov registry record
Validation of Brain Function Assessment Algorithm for mTBI/Concussion
A clinical trial, sponsored by BrainScope Company.
- Completed
- Registry status
- 309
- Enrollment target
NCT03671083: Completed study, sponsored by BrainScope Company.
NCT03671083 is a clinical trial that has completed, run by BrainScope Company. The registered enrollment target is 309 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03671083 has completed, sponsored by BrainScope Company.
- COMPLETED
- Registry status
- 309 participants
- Enrollment target
Study Summary
This study is Part 2 of data collection from 13-25 years old subject population for validation of previously derived algorithms. This data will be combined with that collected under NCT02957461 (Part 1 with subject age range 18-25 years) for the final analyses of validation of the algorithms.
Primary Outcome
Sensitivity and specificity forthe identification of the likelihood of concussion/mTBI at the time of injury using a multi-modal EEG-based Concussion Index (CI)
Interventions
- DEVICE BrainScope Ahead 300iP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2019-03-29 |
What the finished NCT03671083 record still lists
NCT03671083 is an observational study that tracks outcomes without assigning an intervention. The registered 309 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which BrainScope Ahead 300iP is the first listed.
NCT03671083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03671083 about?
NCT03671083 is a clinical study titled "Validation of Brain Function Assessment Algorithm for mTBI/Concussion". This study is Part 2 of data collection from 13-25 years old subject population for validation of previously derived algorithms. This data will be combined with that collected under NCT02957461 (Part 1 with subject age range 18-25 years) for the final analyses of validation of the algorithms.
What is the current status of trial NCT03671083?
This trial is currently completed. The enrollment target is 309 participants. The study started on 2018-10-01. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03671083?
The interventions under investigation include: BrainScope Ahead 300iP (DEVICE).
Who is sponsoring clinical trial NCT03671083?
This trial is sponsored by BrainScope Company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03011684 · 309 participants · Phase 3
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
- NCT06915233 · 309 participants · Phase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI